NRx Pharmaceuticals Transitions to Commercial Stage Following FDA Approval and Q3 2026 Earnings
NRx Pharmaceuticals (NRXP) has officially transitioned from a clinical-stage company to a commercial biopharmaceutical entity following the October 29, 2026, FDA approval of its preservative-free ketamine drug-device combination. Utilizing blow-fill-seal technology, the new packaging offers significant unit cost savings compared to traditional glass vials and enhances manufacturing throughput capacity to up to 5 million units per month. Financially, the company reported Q3 net revenue of $1.2 million, driven by the expansion of its HOPE Therapeutics clinical operations. While the company recorded a quarterly net loss of $2.2 million, this represents an improvement over the prior comparable quarter due to debt restructuring and accounting adjustments. NRx is also leveraging a $11.2 million DARPA contract for the SPARC-TMS clinical trial targeting depression and PTSD in military populations.

Tickers: $NRXP
Topics: clinical trials earnings report FDA approval government contract revenue growth
Read the full article at Motley Fool
Part of the story NRx Pharmaceuticals Transitions to Commercial Stage Following FDA Approval and Q3 2026 Earnings (2 articles)